Disease therapeutics

  • 345 views
Uploaded on

the industry analysis specialist, has released its new reports” Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020

the industry analysis specialist, has released its new reports” Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
345
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
3
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020http://www.aarkstore.com/search/viewresults.asp?search=DiseaseTherapeutics&PubId=&pagenum=1the industry analysis specialist, has released its new reports” Disease Therapeutics - Global DrugForecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysison the global therapeutics market. It provides comprehensive market information, highlighting thetreatment guidelines and identifying and analyzing the key trends shaping and driving the global market.It analyzes treatment usage patterns and provides insights into the competitive landscape and theemerging players expected to significantly alter the positions of the market leaders. The report providesvaluable insights into the pipeline products and quantifies the unmet need within the global PDtherapeutics market and as well as in the individual markets of the US and the top five countries inEurope, highlighting opportunities for future players.KeywordsMarket forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products,pipeline, promising drugs, future players, key companies, strategic competitor assessment, marketcharacterization, implications for future market, mechanism of action, oncology, cancer, treatmentguideline, target product profile, clinicians endpoints, disease overview, colorectal cancer drug sales, UScolorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germanycolorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japancolorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, ChinaRelated ReportsGraves’ Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019 Feb 2012http://www.aarkstore.com/reports/Graves’-Disease-Therapeutics-Pipeline-Assessment-and-Market-Forecast-to-2019-192633.html
  • 2. ScopeThe report provides information on the key drivers and challenges of the Graves Disease Therapeuticsmarket. Its scope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Graves DiseaseTherapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.The report provides information on the key drivers and challenges of the Graves Disease Therapeuticsmarket. Its scope includes -- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Graves DiseaseTherapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.- Pipeline analysis data providing a split across the different phases, mechanisms of action beingdeveloped and emerging trends by seven key markets. Pipeline candidates fall under major therapeuticclasses.- Analysis of the current and future competition in the seven key countries Graves Disease Therapeuticsmarket.- Insightful review of the key industry drivers, restraints and challenges. Each trend is independentlyresearched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization, unmet needs andthe implications for the Graves Disease Therapeutics market.- Analysis of key recent licensing and partnership agreements in Graves Disease Therapeutics marketAbout CompanyMarket Research Reports Distributor - Aarkstore.com have vast database on market research reports,company financials, company profiles, SWOT analysis, company report, company statistics, strategyreview, industry report, industry research to provide excellent and innovative service to our reportbuyers.
  • 3. Related Reports:Parkinsons Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020 Feb 2012http://www.aarkstore.com/reports/Parkinson-s-Disease-Therapeutics-Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-198860.htmlThis report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by GlobalData’s team of industry experts. In 2011, the global Parkinson’s Disease (PD) therapeutics market, which includes the key markets of theUS, Japan, Germany, the UK, France, Italy, Spain, Brazil, China, India and Russia was estimated to beworth $2,992m. During the period 2002-2011, the global PD therapeutics market grew at a CompoundAnnual Growth Rate (CAGR) of 5.8%. GlobalData analysis shows that the market size was primarilydriven by two key parameters: the increase in PD prevalence due to the increase in the aging populationin the 11 key markets and the increasing cost of therapy. In 2011, the market registered a decline in themarket valuations due to the entry of generics for Mirapex (pramipexole) and higher preference forgeneric ropinirole.The global PD therapeutics market is primarily served by levodopa, dopamineagonists, Monoamine Oxidase Inhibitors (MAO-BI) and Catechol-O-Methyltransferase (COMT) inhibitors.The market is dominated by branded products such as Boehringer Ingelheim’sMirapex/Mirapexin/Sifrol/MirapexER/MirapexinER (pramipexole), GlaxoSmithKline’s (GSK)Requip/RequipXL(ropinirole),Orion/Novartis’ Stalevo/Comtan (carbidopa/levodopa/entacapone) andTeva/Lundbeck’s Azilect/Agilect (rasagiline). In addition, a large number of generics are also available inthis market. The global PD therapeutics market is expected to grow at a modest CAGR of 2.2% and isforecast to reach $3,650m by 2020. The modest growth rate has been attributed to patent expiries ofthe major drugs, the subsequent entry of generics and the weak late stage developmental pipeline.Gaucher’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Jan 2012http://www.aarkstore.com/reports/Gauchers-Disease-Therapeutics-Pipeline-Assessment-and-
  • 4. Market-Forecasts-to-2018-170093.htmlFabrys Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Dec 2011Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Dec 2011Fabry’s Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Dec 2011Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Dec 2011Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and MarketForecasts to 2018 Nov 2011Periodontal Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Nov 2011Rare Disease Therapeutics, Inc.-Therapeutic Competitors Report Mar 2011Rare Disease Therapeutics, Inc.-Detailed Product Pipeline Jan 2011Lyme disease Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Dec 2010Rare Disease Therapeutics, Inc.-Company Report April 2010Aarkstore EnterpriseJessicaSupport TeamMobile: +918149852585Office: +912227453309